8-K: Checkpoint Therapeutics Provides First Quarter 2024 Financial Update and Cosibelimab BLA Resubmission Plans

Checkpoint Therapeutics announced its first quarter 2024 financial results and provided an update on its plans to resubmit the Biologics License Application (BLA) for cosibelimab.

Summary

• Checkpoint Therapeutics reported a net loss of $10.9 million, or $0.33 per share, for the first quarter of 2024, compared to a net loss of $10.5 million, or $0.89 per share, for the same period in 2023.
• The company's cash and cash equivalents increased to $11.2 million as of March 31, 2024, up from $4.9 million at the end of 2023.
• Research and development expenses decreased to $8.5 million in Q1 2024 from $15.8 million in Q1 2023.
• General and administrative expenses increased slightly to $2.5 million in Q1 2024 from $2.3 million in Q1 2023.
• Checkpoint is working with its contract manufacturing organization (CMO) to address deficiencies noted by the FDA in a Complete Response Letter (CRL) for cosibelimab.
• The company plans to meet with the FDA to align on a potential mid-year BLA resubmission for cosibelimab.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company has improved its cash position and reduced R&D expenses, the FDA's CRL and the resulting delay in the BLA resubmission are significant concerns. The company is actively working to address these issues, but the outcome is uncertain.

Positives

• The company's cash position has improved significantly, providing more financial stability.
• Research and development expenses have decreased, indicating improved cost management.
• The company is actively working to address the FDA's concerns regarding cosibelimab's manufacturing, with a potential BLA resubmission targeted for mid-year.
• The company successfully raised $14 million through a registered direct offering and private placement.
• The appointment of a new non-executive director adds expertise to the board.

Negatives

• The company experienced a net loss of $10.9 million in the first quarter of 2024.
• The FDA issued a Complete Response Letter (CRL) for the cosibelimab BLA, citing manufacturing issues.
• The company is dependent on a third-party CMO to resolve manufacturing deficiencies.

Risks

• The company's ability to successfully address the FDA's concerns and resubmit the BLA for cosibelimab is not guaranteed.
• There is a risk that the FDA may not accept the resubmitted BLA or that the approval process may be further delayed.
• The company is dependent on third-party suppliers and contract manufacturing organizations.
• The company needs substantial additional funds to continue operations and development.
• There are risks associated with the clinical trial data, including potential safety issues or failure to meet secondary endpoints.

Future Outlook

The company plans to meet with the FDA to align on a potential mid-year BLA resubmission for cosibelimab and is working to address the issues raised in the CRL. They are also working to shorten the launch timeline in anticipation of a potential approval.

Management Comments

• James F. Oliviero, President and CEO, stated that they have been working closely with their CMO to resolve inspection deficiencies noted in the CRL.
• Oliviero believes the CMO's response to the inspection deficiencies could allow for the resubmission of the BLA.

Industry Context

This announcement is relevant to the oncology and immunotherapy sectors, particularly companies developing treatments for solid tumor cancers. The focus on addressing manufacturing issues and regulatory hurdles is common in the pharmaceutical industry, especially for biologics. The company's progress with cosibelimab is being closely watched by investors and competitors in the anti-PD-L1 antibody space.

Comparison to Industry Standards

• The decrease in R&D expenses from $15.8 million to $8.5 million year-over-year is significant and could be a result of the company focusing on the BLA resubmission rather than new research projects. This is a common strategy for companies in the clinical stage.
• The increase in cash position from $4.9 million to $11.2 million is a positive sign, as many biotech companies struggle with funding. This was achieved through a registered direct offering and private placement, which is a common method for raising capital in the biotech industry.
• The FDA's CRL citing manufacturing issues is not uncommon in the pharmaceutical industry, and many companies face similar challenges. For example, companies like Catalent have faced similar issues with manufacturing facilities.
• The company's focus on cosibelimab, a potential best-in-class anti-PD-L1 antibody, puts it in competition with established players like Merck's Keytruda and Bristol-Myers Squibb's Opdivo. However, Checkpoint is highlighting a potentially favorable safety profile and a two-fold mechanism of action as differentiators.

Management Changes

Related Party Transactions

• The company reported revenue of $0 from related parties for the three months ended March 31, 2024, compared to $35 for the same period in 2023.
• Accounts payable and accrued expenses to related parties were $2.9 million as of March 31, 2024, compared to $2.8 million as of December 31, 2023.

Stakeholder Impact

• Shareholders may be concerned about the delay in the BLA resubmission and the potential impact on the company's stock price.
• Employees may be affected by the company's financial performance and the uncertainty surrounding the regulatory approval process.
• Customers (potential patients) may experience a delay in access to cosibelimab.
• Suppliers and creditors may be impacted by the company's financial situation and ability to meet its obligations.

Next Steps

• The company plans to meet with the FDA to align on a potential mid-year BLA resubmission for cosibelimab.
• Checkpoint will continue to work with its third-party CMO to address the manufacturing deficiencies identified by the FDA.

Key Dates

Keywords

cosibelimab, FDA, BLA, cutaneous squamous cell carcinoma, cSCC, checkpoint therapeutics, biologics license application, manufacturing, clinical trial, oncology, immunotherapy